Oct 2026· European Journal of Preventive Cardiology· 0 citations
Medicine
TL;DR
In CKD patients not yet on kidney replacement therapy, systemic low-grade inflammation, measured through hs-CRP, is associated with occurrence of cardiovascular events independently of traditional risk factors, including a history of ASCVD.
Abstract
Aims
Chronic inflammation is associated with cardiovascular disease in the general population, but data on patients with chronic kidney disease (CKD) are limited. We sought to assess whether systemic low-grade inflammation is independently associated with cardiovascular events in CKD patients not yet on kidney replacement therapy, with or without a history of atherosclerotic cardiovascular disease (ASCVD).
Methods
CKD-REIN is a prospective cohort study of adults with CKD stages 2-5, conducted in 40 French nephrology outpatient facilities. Baseline high-sensitivity plasma C-reactive protein (hs-CRP) was centrally measured using an immunoturbidimetric method. Systemic low-grade inflammation was defined as hs-CRP ≥2 mg/L. Cox proportional hazards models estimated cause-specific hazard ratios (HR) and 95% confidence intervals (CI) for major adverse cardiovascular events (MACE; composite of stroke, myocardial infarction, or cardiovascular death) or hospitalization for heart failure (HHF).
Results
We included 2078 patients: 67% men, mean (SD) age 67(13) years, mean eGFR 36(12) mL/min/1.73 m2, 38% with history of ASCVD, median hs-CRP concentration 2.4 mg/L (inter-quartile range 1.1-5.1). After median follow-up of 5 years, 171 patients had a MACE and 207 had HHF. After controlling for potential confounders, a twofold increase in hs-CRP was associated with a 12% (95% CI 0-26) higher cause-specific hazard of MACE and a 26% (95% CI 13-40) higher cause-specific hazard of HHF.
Conclusion
In CKD patients not yet on kidney replacement therapy, systemic low-grade inflammation, measured through hs-CRP, is associated with occurrence of cardiovascular events independently of traditional risk factors, including a history of ASCVD.
BACKGROUND AND HYPOTHESIS
The burden and prognostic significance of inflammation in chronic kidney disease (CKD) remains poorly characterized, with prior studies yielding conflicting estimates of the association between elevated high-sensitivity C-reactive protein (hsCRP) and cardio-kidney outcomes.
METHODS
Observati...
F. Mazhar, Minjung Han, Katherine R. Tuttle et al.· Nephrology, Dialysis and Tra...· 0 citations
In patients with moderate-to-advanced CKD, previously unrecognised HFpEF was identified in approximately half of participants using guideline-based diagnostic criteria, supporting its role as a rule-in rather than rule-out tool in CKD.
M. Covic, A. Stefan, G. Dodi et al.· European Heart Journal· 0 citations
Atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD) often coexist, worsening patient prognosis. Inflammation, commonly assessed by C-reactive protein (CRP), is a potential therapeutic target. Trials of inflammation-targeted therapies highlight the need for evidence on the clinical impa...
S. Minha, A. E. Alon Eisen, A. R. Ariel Roguin et al.· European Heart Journal· 0 citations
It is suggested that closer monitoring of plasma potassium levels in patients with CKD may improve cardiovascular risk stratification in this population and higher potassium levels were associated with altered cardiac structure and function in patients with CKD.
I. Lenz, J. Christensen, L. Duus et al.· European Heart Journal· 0 citations
Atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD) impact health and healthcare systems. Inflammation is a potential modifiable risk factor for both conditions. The case for evaluating the modification of inflammation in these conditions could be strengthened by evidence that systemic...
Kausik K. Ray, Fotis Barkas, E. Huisman et al.· European Heart Journal Open· 0 citations
Optimal Life’s Essential 8 cardiovascular health is associated with lower risk of MACEs and CKD progression in ASCVD patients, with smoking and glucose as primary modifiable drivers of residual risk for MACEs, and glucose, BMI and smoking for CKD.
Z. Yuan, X. Lu, G. Yuan et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.